PD23-07 WATER VS WATER II: THREE YEAR COMPARISON OF AQUABLATION THERAPY FOR BENIGN PROSTATIC HYPERPLASIA

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology IV (PD23)1 Sep 2021PD23-07 WATER VS WATER II: THREE YEAR COMPARISON OF AQUABLATION THERAPY FOR BENIGN PROSTATIC HYPERPLASIA David-Dan Nguyen, Kevin C. Zorn, and Naeem Bhojani David-Dan NguyenDavid-Dan Nguyen More articles by this author , Kevin C. ZornKevin C. Zorn More articles by this author , and Naeem BhojaniNaeem Bhojani More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002016.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Surgical options are limited when treating large (>80cc) prostates for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Open simple prostatectomy remains the most common procedure performed for large prostates. As such, there is a need for novel surgical approaches with shorter learning curves and effective treatment. Aquablation (AquaBeam System, PROCEPT BioRobotics, Inc., USA), an ultrasound-guided, robotically executed waterjet ablative procedure, could fill this gap. This analysis compares the 3-year outcomes of Aquablation in 30cc to 80cc prostates with the outcomes in 80cc to 150cc prostates. METHODS: WATER (NCT02505919) is a prospective, double-blind, multicenter, international clinical trial comparing the safety and efficacy of Aquablation and TURP in the treatment of LUTS/BPH in men 45 to 80 years old with a prostate between 30cc and 80cc. WATER II (NCT03123250) is a prospective, multicenter, single-arm international clinical trial of Aquablation in men with a prostate between 80cc and 150cc. We compare 36-month outcomes amongst 116 WATER and 101 WATER II study subjects undergoing Aquablation. Students’ t-test or Wilcoxon tests were used for continuous variables and Fisher’s test for binary variables. RESULTS: International Prostate Symptom Score (IPSS) scores improved from 22.9 and 23.2 at baseline in WATER and WATER II, respectively, to 8.0 and 6.4 at 36 months, with 36-month reductions of 14.4 and 16.7 points, respectively (p=.07 for difference in change scores). At baseline, urinary flow rate (Qmax) was 9.4 and 8.7 cc/sec in WATER and WATER II, improving to 20.6 and 19.0 cc/sec, respectively (p=.70 for difference in change scores) at 36 months. Improvements in both IPSS and Qmax were immediate and sustained throughout follow-up. Change in IPSS, Qmax, and post-void residual (PVR) can be found in Figure 1. CONCLUSIONS: Aquablation clinically normalizes outcomes between patients with a 30cc to 80cc prostate and patients with an 80cc to 150cc prostate treated for LUTS/BPH. It is effective in patients with large prostate glands (>80cc) with acceptable complications out to three years. Source of Funding: The WATER and WATER II clinical trials are funded by PROCEPT BioRobotics. This abstract is submitted on behalf of all WATER and WATER II investigators © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e422-e423 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information David-Dan Nguyen More articles by this author Kevin C. Zorn More articles by this author Naeem Bhojani More articles by this author Expand All Advertisement Loading ...